Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
6 evidence topics · 4 sources
Combination: company description of the target and the two components
Combination: noradrenergic excitation and antimuscarinic disinhibition of the hypoglossal motor nucleus
“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine, a selective norepinephrine reuptake inhibitor, was expected to increase synaptic norepinephrine and enhance central excitatory drive to upper airway motor neurons, thereby improving dilator muscle tone. Aroxybutynin, a selective antimuscarinic agent, was hypothesized to reduce muscarinic inhibition of HMN activity (Figures 1 and 2). Together, this dual mechanism was designed to stabilize upper airway muscle activation across NREM and REM sleep and mitigate sleep-related relaxation of the airway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combination: proposed mechanism by which aroxybutynin offsets the wake-promoting effect of atomoxetine, not yet shown in animal models
Aroxybutynin: the R-enantiomer of racemic oxybutynin
“AD109 refined the original combination by substituting oxybutynin with aroxybutynin, the R-enantiomer that mediates most of oxybutynin’s antimuscarinic actions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Concentrating the pharmacologic activity in a single active stereoisomer allows for equivalent effects on the upper airway at a lower total dose, with the potential for fewer off-target effects and better overall tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote